AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 463541 — intervention group
Group type: COMPARATOR
Intervention: Long end‐hole catheter
Number of subjects: 71
Study 31347438 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line filtration
Number of subjects: 268
Study 31347438 — intervention group
Group type: COMPARATOR
Intervention: No filtration (control group)
Number of subjects: 268
Study 31180833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid robotic system combining EMG-Triggered FES with a passive exoskeleton for upper limb suspension during a structured exercise program of 27 sessions lasting 30 min each.
Number of subjects: 7
Study 31180833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid robotic system
Number of subjects: 7
Study 28326680 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.3 μg/kg administered 30 min before surgery
Number of subjects: 48
Study 28326680 — intervention group
Group type: COMPARATOR
Intervention: Normal saline administered 30 min before surgery
Number of subjects: 48
Study 25875679 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental RGP lens (ExpRGP)
Number of subjects: 52
Study 25875679 — intervention group
Group type: COMPARATOR
Intervention: Standard RGP lens (StdRGP)
Number of subjects: 52
Study 25875679 — intervention group
Group type: COMPARATOR
Intervention: No lens (baseline)
Number of subjects: 52
Study 25007542 — intervention group
Group type: EXPERIMENTAL
Intervention: Active light treatment (ALT)
Number of subjects: 24
Study 25007542 — intervention group
Group type: COMPARATOR
Intervention: Placebo light treatment (L-PBO)
Number of subjects: 24
Study 17310659 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 69
Study 17310659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurveda
Number of subjects: 69
Study 17310659 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 69
Study 15023808 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 6 weeks, then 80 mg/d for 6 weeks, then 80 mg/d for 24 weeks
Number of subjects: 39
Study 15023808 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d for 6 weeks, then 40 mg/d for 6 weeks, then 80 mg/d for 24 weeks
Number of subjects: 39
Study 15023808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 39
Study 11029999 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Dates program
Number of subjects: 14
Study 9280743 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (prepidil gel) plus oxitocin
Number of subjects: 30
Study 9280743 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxitocin
Number of subjects: 30
Study 8397562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg oral dose)
Number of subjects: 52
Study 8397562 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (subcutaneous injection)
Number of subjects: 52
Study 8397562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 52
Study 8397562 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 52
Study 3628702 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy 1 (erythromycin, nitrofurantoin substituted for trimethoprim and ampicillin)
Number of subjects: 2
Study 3628702 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy 2 (Augmentin - ampicillin + clavulinic acid substituted for trimethoprim and ampicillin)
Number of subjects: 2
Study 3628702 — intervention group
Group type: COMPARATOR
Intervention: Pre-policy period
Number of subjects: 2
Study 31094286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloplegic auto‐refraction
Number of subjects: 2248
Study 31094286 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐cycloplegic auto‐refraction (NCAR)
Number of subjects: 2248
Study 31094286 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity (UCVA)
Number of subjects: 2248
Study 31094286 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of UCVA and NCAR
Number of subjects: 2248
Study 29203689 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel interactive visualization of ESCAPE trial data
Number of subjects: 0
Study 29203689 — intervention group
Group type: COMPARATOR
Intervention: Traditional visualization of ESCAPE trial data
Number of subjects: 0
Study 27452202 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, increased to 150 mg if week 8 LDL-C ≥2.6/3.1 mmol/L)
Number of subjects: 216
Study 27452202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 27452202 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 216
Study 24666814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tip variant
Number of subjects: 111
Study 24666814 — intervention group
Group type: EXPERIMENTAL
Intervention: Perihilar variant
Number of subjects: 111
Study 24666814 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS variant
Number of subjects: 111
Study 24666814 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 111
Study 22082200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release oxycodone tablets (initial dose of 10mg orally every 12 hours, titrated according to pain intensity)
Number of subjects: 80
Study 22082200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release oxycodone tablets
Number of subjects: 80
Study 19329063 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Simplus (Bausch & Lomb) multipurpose solution
Number of subjects: 18
Study 19329063 — intervention group
Group type: COMPARATOR
Intervention: Boston Advance (Boston) care system
Number of subjects: 18
Study 17454160 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2)/norethisterone acetate (NETA) (50 microg E2 daily for 14 days followed by 50 microg E2/0.25 microg NETA daily for 14 days; transdermal group, n = 19)
Number of subjects: 59
Study 17454160 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal continuous E2/oral medroxyprogesterone acetate (MPA) (50 microg E2/5 mg MPA daily; transdermal/oral group, n = 19)
Number of subjects: 59
Study 17454160 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral continuous E2/NETA (1 mg E2/0.5 mg NETA daily; oral group, n = 21)
Number of subjects: 59
Study 17454160 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effects of HRT
Number of subjects: 59
Study 17454160 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased-risk group (WC <88 cm, n = 32)
Number of subjects: 59
Study 17454160 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (WC >=88 cm, n = 27)
Number of subjects: 59
Study 17454160 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fat <33 mm (n = 29)
Number of subjects: 59
Study 17454160 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fat >=33 mm (n = 30)
Number of subjects: 59
Study 14962821 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 600 mg
Number of subjects: 35
Study 14962821 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 900 mg
Number of subjects: 35
Study 14962821 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 1200 mg
Number of subjects: 35
Study 14962821 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine (all doses)
Number of subjects: 35
Study 14962821 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine
Number of subjects: 35
Study 11856080 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide, 6.75 g
Number of subjects: 50
Study 11856080 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine, 3 g
Number of subjects: 50
Study 9788001 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment
Number of subjects: 286
Study 8711365 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyene phosphatidylcholine (PPC) 2.7 g daily for three months
Number of subjects: 30
Study 8711365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2532946 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone suppression test (DST) positive
Number of subjects: 105
Study 2532946 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone suppression test (DST) negative
Number of subjects: 105
Study 2532946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 335247 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg given twice daily
Number of subjects: 95
Study 335247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 30709403 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nutrition intervention targeting increased whole plant food intake
Number of subjects: 136
Study 30709403 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 28556488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit anti-human thymocyte immunoglobulin (rATG)
Number of subjects: 1
Study 28556488 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab
Number of subjects: 1
Study 25776840 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingre Quyu Granule (QQG)
Number of subjects: 96
Study 25776840 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 96
Study 24325795 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity, 40 s, buccal
Number of subjects: 60
Study 24325795 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity, 40 s, lingual
Number of subjects: 60
Study 24325795 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 60
Study 24325795 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental groups (not specified)
Number of subjects: 60
Study 22336009 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with Alutard SQ, ALK-Abell¨®
Number of subjects: 98
Study 22336009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Chanllergen-Df drops, Wolwo Pharma
Number of subjects: 98
Study 19500919 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 68
Study 17999779 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC 1.8 g.day(‐1), 3 days)
Number of subjects: 55
Study 17999779 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid (LIP 1.2 g.day(‐1), 3 days)
Number of subjects: 55
Study 17999779 — intervention group
Group type: EXPERIMENTAL
Intervention: taurine (TAU 3 g.day(‐1), 3 days)
Number of subjects: 55
Study 17999779 — intervention group
Group type: COMPARATOR
Intervention: Control (CON, placebo)
Number of subjects: 55
Study 15697072 — intervention group
Group type: COMPARATOR
Intervention: Flutamide 250 mg daily
Number of subjects: 30
Study 15697072 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg three times daily
Number of subjects: 30
Study 11696874 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iron oxide particles with high soluble iron content
Number of subjects: 16
Study 11696874 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iron oxide particles with low soluble iron content
Number of subjects: 16
Study 11696874 — intervention group
Group type: COMPARATOR
Intervention: Inhaled iron oxide particles (both high and low soluble iron)
Number of subjects: 16
Study 9043725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 24
Study 9043725 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24
Study 9043725 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane + N2O
Number of subjects: 24
Study 9043725 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane + N2O
Number of subjects: 24
Study 8198915 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of packing the external auditory meatus and concha
Number of subjects: 0
Study 8198915 — intervention group
Group type: COMPARATOR
Intervention: Packing the external auditory meatus and concha
Number of subjects: 0
Study 2903202 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (5%)
Number of subjects: 28
Study 2903202 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (0.5%)
Number of subjects: 28
Study 2903202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 28650073 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship education program
Number of subjects: 32
Study 28650073 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 32
Study 27569726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine Bitartrate Delayed Release (CBDR)
Number of subjects: 169
Study 27569726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 24738317 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing group (marcel materials used for nasal packing after septoplasty)
Number of subjects: 90
Study 24738317 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal suture group (septal suture technique performed after septoplasty)
Number of subjects: 90
Study 24738317 — intervention group
Group type: EXPERIMENTAL
Intervention: VSD group (one drainage tube used for negative pressure sucking after septoplasty without nasal packing)
Number of subjects: 90
Study 23853057 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000mg of American ginseng
Number of subjects: 364
Study 23853057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 20629971 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac) with mycophenolate mofetil (MMF)
Number of subjects: 300
Study 20629971 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) with azathioprine (Aza)
Number of subjects: 300
Study 20629971 — intervention group
Group type: EXPERIMENTAL
Intervention: D+/R- combination
Number of subjects: 300
Study 20629971 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive strategy
Number of subjects: 300
Study 20629971 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered renal function
Number of subjects: 300
Study 18923348 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic colorectal surgery
Number of subjects: 0
Study 16164659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Number of subjects: 129
Study 16164659 — intervention group
Group type: COMPARATOR
Intervention: Calcium containing phosphate binders
Number of subjects: 129
Study 14513039 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐FISH on peripheral blood neutrophils
Number of subjects: 0
Study 14513039 — intervention group
Group type: COMPARATOR
Intervention: I‐FISH on unselected PB white cells
Number of subjects: 0
Study 14513039 — intervention group
Group type: COMPARATOR
Intervention: Cytogenetics
Number of subjects: 0
Study 10994909 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exercise (50 biceps curls with a 5-lb dumbbell)
Number of subjects: 26
Study 10994909 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization (arm placed in a cast and supported in a sling at 90 degrees)
Number of subjects: 26
Study 10994909 — intervention group
Group type: COMPARATOR
Intervention: Control (no restriction of arm activity)
Number of subjects: 26
Study 8849766 — intervention group
Group type: EXPERIMENTAL
Intervention: Invited group (mammography screening)
Number of subjects: 15795
Study 8849766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mammography screening)
Number of subjects: 15795
Study 8849766 — intervention group
Group type: COMPARATOR
Intervention: General Swedish women
Number of subjects: 15795
Study 1593749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan (2.5 mg, intravenous)
Number of subjects: 0
Study 1593749 — intervention group
Group type: COMPARATOR
Intervention: Captopril (12.5 mg, orally)
Number of subjects: 0
Study 1593749 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pimobendan and captopril
Number of subjects: 0
Study 6321686 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen (20 mg/m2 on days 2-6) and premarin (0.625 mg every 12 hours for three days on day 7)
Number of subjects: 110
Study 6321686 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (cytoxan 750 mg/m2 and Adriamycin 30 mg/m2 on day 1 plus 5‐fluorouracil 500 mg/m2 and methotrexate 40 mg/m2 on day 8)
Number of subjects: 110
Study 6321686 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen and premarin
Number of subjects: 110
Study 6321686 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 110
Study 31820334 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitored exercise rehabilitation
Number of subjects: 96
Study 31820334 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up (Control)
Number of subjects: 96
Study 31357402 — intervention group
Group type: COMPARATOR
Intervention: Usual-salt diet (1.2% salt)
Number of subjects: 97
Study 26925988 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention for family caregivers
Number of subjects: 82
Study 26516308 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 30 mg/kg followed by 10 mg/kg/h continuous infusion until the end of surgery
Number of subjects: 146
Study 26516308 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg
Number of subjects: 146
Study 23855066 — intervention group
Group type: COMPARATOR
Intervention: Inflated Vest
Number of subjects: 10
Study 23855066 — intervention group
Group type: EXPERIMENTAL
Intervention: Jacket
Number of subjects: 10
Study 23855066 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 10
Study 23855066 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 21291422 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane preconditioning and propofol postconditioning (group IP)
Number of subjects: 120
Study 21291422 — intervention group
Group type: COMPARATOR
Intervention: Propofol treatment (group P)
Number of subjects: 120
Study 21291422 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane treatment (group I)
Number of subjects: 120
Study 21291422 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 120
Study 20187487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive self-assessment
Number of subjects: 86
Study 20187487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-motor self-assessment
Number of subjects: 86
Study 20187487 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 20187487 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention (2 weeks later)
Number of subjects: 86
Study 17121064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole nitrate cream 2% applied twice daily for 4 weeks
Number of subjects: 588
Study 17121064 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 4 weeks
Number of subjects: 588
Study 12734156 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine PCA alone (Group I, n = 15)
Number of subjects: 35
Study 12734156 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine PCA plus a continuous basal infusion (Group II, n = 14)
Number of subjects: 35
Study 12734156 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 35
Study 12734156 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 35
Study 12734156 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II
Number of subjects: 35
Study 10348755 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine monotherapy (low target arm)
Number of subjects: 113
Study 10348755 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine monotherapy (middle target arm)
Number of subjects: 113
Study 10348755 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine monotherapy (high target arm)
Number of subjects: 113
Study 10348755 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine monotherapy (pooled arms)
Number of subjects: 113
Study 10348755 — intervention group
Group type: COMPARATOR
Intervention: Nucleoside control therapy (zidovudine or didanosine)
Number of subjects: 113
Study 8664036 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 200 or 300 mg/m2/day by prolonged ambulatory infusion with radiotherapy (60-66 Gy)
Number of subjects: 39
Study 8664036 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) with radiotherapy
Number of subjects: 39
Study 1960007 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose yohimbine (peak dose, 43 mg/day)
Number of subjects: 47
Study 1960007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 6264376 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-containing oral rehydration solution
Number of subjects: 784
Study 6264376 — intervention group
Group type: COMPARATOR
Intervention: Sucrose-containing oral rehydration solution
Number of subjects: 784
Study 6264376 — intervention group
Group type: EXPERIMENTAL
Intervention: Both glucose and sucrose solutions
Number of subjects: 784
Study 6500778 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincamine teprosilate (Teproside) at 120 mg daily for 90 days
Number of subjects: 30
Study 6500778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29616706 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanezumab
Number of subjects: 0
Study 29616706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26291330 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing CHC
Number of subjects: 34
Study 26291330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 24862170 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sweetened beverages (NNS)
Number of subjects: 303
Study 24862170 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 303
Study 22651831 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 0
Study 22651831 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 19997751 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Image Cytometry (DICM)
Number of subjects: 93
Study 19997751 — intervention group
Group type: COMPARATOR
Intervention: Diploid DICM
Number of subjects: 93